SPRY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

26.90M

-68.93%

-0.432

-184.64%

25.30M

+217.32%

-0.482

+37.86%

39.83M

+153.39%

-0.405

-11.96%

Estimates Revision

The market is revising Upward the revenue expectations for ARS Pharmaceuticals, Inc. (SPRY) for FY2025, with the revenue forecasts being adjusted by 2.02% over the past three months. During the same period, the stock price has changed by 19.49%.

Revenue Estimates for FY2025

Revise Upward

+2.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.9%

In Past 3 Month

Stock Price

Go Up

+19.49%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

30.00

High

35.00

Current: 0.000

Low

25.00

Averages

30.00

High

35.00

Oppenheimer

Outperform

maintain

$40 -> $35

2025-11-11

Reason

Oppenheimer

Price Target

$40 -> $35

2025-11-11

maintain

Outperform

Reason

Oppenheimer lowered the firm's price target on ARS Pharmaceuticals to $35 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 financials with $32.5M in revenue, beating consensus and surpassing OpCo estimates of $28.7M/$29.4M, respectively. Neffy's momentum reflects the DTC lift, back-to-school demand, and broader prescriber adoption across new epinephrine segments, with upcoming tailwinds from the virtual campaign, growing real-world evidence, and formulary adds in 2026, Oppenheimer adds.

Roth Capital

Kyle Bauser

initiated

$30

2025-11-04

Reason

Roth Capital

Kyle Bauser

Price Target

$30

2025-11-04

initiated

Reason

Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals with a Buy rating and $30 price target. The firm is anticipating significant revenue growth from the rapid adoption of the company's signature product, neffy, which is an innovative intranasal epinephrine device for Type 1 allergic reactions, including anaphylaxis, the analyst tells investors in a research note. The ability of neffy to take significant share from outdated epinephrine auto-injectors is currently underappreciated, particularly given the recent sales growth to date, the firm added.

Roth Capital

NULL -> Buy

initiated

$40

2025-09-04

Reason

Roth Capital

Price Target

$40

2025-09-04

initiated

NULL -> Buy

Reason

Roth Capital initiated coverage of ARS Pharmaceuticals with a Buy rating and $40 price target.

Roth Capital

Jason Wittes

Buy

initiated

$40

2025-09-04

Reason

Roth Capital

Jason Wittes

Price Target

$40

2025-09-04

initiated

Buy

Reason

As previously reported, Roth Capital analyst Jason Wittes initiated coverage of ARS Pharmaceuticals with a Buy rating and $40 price target. The firm calls the company's neffy - the first needle-free way to administer epinephrine - a "vast improvement" over auto-injectors in terms of safety, dosing, and the form factor, and with 93% commercial payer coverage and a DTC campaign underway, it sees and "aggressive ramp" in sales leading to at least 60% share of the epinephrine market, the analyst tells investors in a research note. Roth further cites the company having a "$3B market opportunity" and upside from market expansion.

Scotiabank

Louise Chen

Buy

Initiates

$30

2025-03-07

Reason

Scotiabank

Louise Chen

Price Target

$30

2025-03-07

Initiates

Buy

Reason

Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals with an Outperform rating and $30 price target. The firm says it is "time to take a look" at ARS shares "ahead of tailwinds that could drive robust uptake" of its newly launched neffy, a nasal spray alternative to epinephrine injections for severe allergic reactions. The share setup is good, with a product that addresses unmet needs, an experienced management team to launch it, and a price that is more affordable than generic epinephrine injections, the analyst tells investors in a research note.

Raymond James

Ryan Deschner

Strong Buy

Maintains

$26 → $28

2025-01-14

Reason

Raymond James

Ryan Deschner

Price Target

$26 → $28

2025-01-14

Maintains

Strong Buy

Reason

Raymond James raised the firm's price target on ARS Pharmaceuticals to $28 from $26 and keeps a Strong Buy rating on the shares. ARS Pharmaceuticals pre-announced Q4 net sales of $6.5M, well above Street estimates, driven by increasing awareness and patient access, the analyst tells investors in a research note. Based on ARS's disclosure that roughly 14,500 neffy 2-packs were delivered in the fourth quarter, script data implies a capture rate of about 60% this quarter, which is very low but "unsurprising" given the early stage of the launch, the firm says.

Valuation Metrics

The current forward P/E ratio for ARS Pharmaceuticals Inc (SPRY.O) is -7.61, compared to its 5-year average forward P/E of -11.43. For a more detailed relative valuation and DCF analysis to assess ARS Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.43

Current PE

-7.61

Overvalued PE

-6.97

Undervalued PE

-15.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.30

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.20

Undervalued EV/EBITDA

-4.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5759.43

Current PS

6.92

Overvalued PS

25289.45

Undervalued PS

-13770.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 326% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SPRY News & Events

Events Timeline

No data

News

5.0

01-09Benzinga

ARS Pharmaceuticals Stock Rises 18.86% Following FDA Update on Rival Aquestive

9.0

01-09Benzinga

Aquestive Therapeutics Faces 40% Stock Drop After FDA Identifies Deficiencies in Anaphylm NDA

9.0

01-02NASDAQ.COM

ARS Pharma's Neffy Approved in China for Allergy Treatment

People Also Watch

Frequently Asked Questions

What is ARS Pharmaceuticals Inc (SPRY) stock price today?

The current price of SPRY is 13.06 USD — it has increased 19.27 % in the last trading day.

What is ARS Pharmaceuticals Inc (SPRY)'s business?

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

What is the price predicton of SPRY Stock?

What is ARS Pharmaceuticals Inc (SPRY)'s revenue for the last quarter?

ARS Pharmaceuticals Inc revenue for the last quarter amounts to 32.50M USD, increased 1471.62 % YoY.

What is ARS Pharmaceuticals Inc (SPRY)'s earnings per share (EPS) for the last quarter?

ARS Pharmaceuticals Inc. EPS for the last quarter amounts to -0.52 USD, increased 160.00 % YoY.

What changes have occurred in the market's expectations for ARS Pharmaceuticals Inc (SPRY)'s fundamentals?

How many employees does ARS Pharmaceuticals Inc (SPRY). have?

ARS Pharmaceuticals Inc (SPRY) has 155 emplpoyees as of January 11 2026.

What is ARS Pharmaceuticals Inc (SPRY) market cap?

Today SPRY has the market capitalization of 1.29B USD.